The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of ...

Shares of healthcare insurance company Molina Healthcare (NYSE:MOH) fell 3.8% in the afternoon session after TD Cowen lowered ...

Biogen is investing $2 billion in its U.S. manufacturing footprint — but not in Massachusetts, where the drug company is ...

Shares of healthcare tech company Privia Health Group (NASDAQ:PRVA) jumped 3.4% in the morning session as investors ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

A strategic milestone for the capital to strengthen global health security, ensure equitable vaccine access and build resilient supply chains ...

iTeos Therapeutics has agreed to be acquired by privately held Concentra Biosciences in a deal initially worth roughly $385 million. iTeos on Monday said Concentra will pay nearly $10.05 a share in ...

Located in KEZAD and operated by Rafed, a subsidiary of PureHealth, the hub was developed in collaboration with the DoH, Abu ...

The logistics centre, developed by authorities in the capital in partnership with pharmaceutical giant GlaxoSmithKline, has ...

Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate of Abu Dhabi, has announced the operational launch of the re ...

Most Oncologic Drugs Advisory Committee members took issue with the lack of dosing optimization and the lack of US patient ...